10:19 AM EDT, 10/04/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Friday it is discontinuing a phase 2 field study assessing the efficacy of its investigational antiviral drug mosnodenvir for the prevention of dengue virus.

The discontinuation is part of a reprioritization of company's communicable diseases research and development portfolio, J&J said, adding that no safety issues were found.

Johnson & Johnson ( JNJ ) shares were down 0.6% in recent trading.

Price: 159.63, Change: -0.88, Percent Change: -0.55